News Board

Hercules Capital told investors it had a disciplined system. Rigorous due diligence. Careful valuations. A growing portfolio. But the story investors got… may not have been the real one. From May 2025 through early 2026, the company reported rising portfolio values and steady net asset value, even highlighting what it called a multi step, carefully...Read more

Power Solutions told investors it was tapping into booming data center demand. High growth. Higher margins. A booming future. But behind the scenes, that story was starting to crack. In May 2025, the company reported record results and strong demand from data centers. By August, executives doubled down, pointing to strong demand and growth tied...Read more

Concorde told investors it offered technology-driven security services with recurring revenue. But according to a recently filed complaint, a coordinated promotion scheme was driving the stock. In April 2025, Concorde went public at $4 a share, highlighting recurring revenue and technology-based services. By June, executives were still touting growth and new contracts. But according to...Read more

On May 5, 2026, two Co-Lead Plaintiffs were appointed in the class action lawsuit captioned Diez v. Richtech Robotics Inc., et al., 2:26-cv-00231. United States Magistrate Judge in the District of Nevada, Maximiliano D. Couvillier III, signed the order that also approved Levi & Korsinsky, LLP and Hagens Berman Sobol Shapiro LLP as Co-Lead Counsel...Read more

Alight told investors a new era had arrived. A seasoned CEO. Strong growth. Reliable dividends. A steady path forward. But behind the scenes, that story was already breaking down. In November 2024, Alight promised improving margins, growing pipeline and improving bookings trends, and a consistent return of capital. By February 2025, they doubled down with...Read more

Gartner told investors growth was accelerating. Projected accelerating contract value growth. Pointing to a path toward double-digit growth. But that story started to crack. In February 2025, executives promised contract value growth would climb toward 12 to 16% in a normal environment. By May, they maintained that outlook, even as macro conditions became more challenging....Read more

Oddity Tech told investors its AI-driven beauty platform was delivering strong growth and profitability. But behind the scenes, something was going very wrong. In February 2025, the company celebrated strong revenue growth and said its direct to consumer strategy was thriving. Through April, August, and November 2025, executives kept raising guidance and promising continued momentum....Read more

Trip.com told investors it was the go to platform for global travel. A powerful one stop shop connecting millions of travelers. The future looked bright. But behind the scenes, a serious threat was building. In April 2024, Trip.com told investors antitrust enforcement in China could affect its business. A year later, Trip.com repeated the same...Read more

Camping World told investors its data-driven inventory strategy was strengthening margins and positioning the company for growth. Smart inventory. Data driven decisions. A stronger balance sheet than ever. But the story behind the numbers was very different. On April 29, 2025, the company reassured investors it could precisely manage inventory and keep margins strong. Executives...Read more

monday.com told investors the future looked huge. AI innovation. Enterprise expansion. A bold goal of $1.8 billion in revenue by 2027. But a recently filed securities lawsuit alleges the story behind the scenes looked very different. In September 2025, executives confidently laid out that massive revenue target at their Investor Day, saying AI adoption and...Read more

Driven Brands told investors its financial reporting was solid. The numbers looked clean. The business looked stable. But according to a newly filed lawsuit, the company’s financial statements were riddled with accounting errors that went back years. Starting in May 2023, the company kept filing financial reports that painted a clean picture. Through 2024 and...Read more

Soleno promised a breakthrough. A first of its kind treatment for a rare disorder. Executives said their drug VYKAT XR was safe, effective, and ready to change lives. But investors later heard a very different story. In March 2025, Soleno celebrated FDA approval of its drug for Prader Willi syndrome. Executives said the clinical data...Read more

Eller v. Vistagen Therapeutics, Inc., et al., 3:26-cv-00427-RS is a lawsuit currently pending in the United States District Court for the Northern District of California. The action was filed on behalf of investors in Vistagen Therapeutics, Inc. (NASDAQ: VTGN) who allegedly suffered losses due to securities fraud by the company. On April 16, 2026, Chief...Read more

Boston Scientific told investors its heart rhythm business was growing fast. Growth looked strong and sustainable. The company said its electrophysiology division would keep expanding, fueled by adoption of its FARAPULSE technology.   But investors say the reality was very different.   In July 2025, executives reported strong results and raised guidance, promising sustained growth...Read more

Aquestive Therapeutics told investors it had developed a breakthrough treatment. A tiny film for severe allergic reactions called Anaphylm. Device free. Easy to carry. Potentially life saving. Executives said the FDA review was on track and approval could come by January 31, 2026. The message stayed the same for months.   In June 2025 the...Read more